Login to Your Account



Merrimack Snags $530M Cancer Antibody Partnership with Sanofi

By Donna Young


Friday, October 2, 2009
In its first major deal, Merrimack Pharmaceuticals Inc. has granted rights to its monoclonal antibody MM-121 to Paris-based drug and vaccine maker Sanofi-Aventis Group SA in exchange for $60 million up front and a potential $470 million in milestones. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription